Fig. 3From: China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapyKaplan–Meier overall survival curves of patients with advanced non-small cell lung cancer in the anlotinib and place armsBack to article page